Literature DB >> 11751492

Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma.

M Fiorentino1, A Altimari, A D'Errico, E Gabusi, P Chieco, M Masetti, W F Grigioni.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: The prognosis for intrahepatic cholangiocarcinoma (ICC) depends mainly on the feasibility of complete surgical resection. In the absence of demonstrated biological predictors of survival, we evaluated the prognostic value of the cyclin-dependent kinase inhibitor p27 by immunohistochemistry in a series of routine specimens from 47 ICC patients, 22 with the hilar and 25 with the peripheral subtype. Proliferation rate was also evaluated in the same cases by the MIB1 index. Tumors were scored as high, low, and negative p27 expressers (> or =50%, <50%, and no positive nuclei, respectively).
RESULTS: High, low, and negative p27 expression was recorded in 18 (38%), 17 (36%), and 12 (26%) cases, respectively. No significant correlation was found between p27 expression and gender, age, tumor grade, tumor location, vascular or perineural invasion, or proliferative index. Tumors with low or absent p27 expression were associated with poor survival compared with the high-expresser group. Kaplan-Meier curves comparing different p27 expression levels with survival showed highly significant separation (P < 0.0001, log-rank test). With univariate Cox proportional hazard regression, only p27 score among all of the parameters was found to influence survival (P = 0.0003).
CONCLUSION: We conclude that in ICC, low or absent p27 expression can predict poor survival, regardless of tumor location, pathological features, and tumor proliferation. Immunohistochemical detection of p27 on routine sections may provide the first biological prognostic marker for ICC, thus influencing the therapeutic strategies for these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751492

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma.

Authors:  Fei Wang; Yulong Liu; Hao Zhang
Journal:  Pathol Oncol Res       Date:  2013-07-14       Impact factor: 3.201

2.  CD24 expression is an independent prognostic marker in cholangiocarcinoma.

Authors:  Shefali Agrawal; Boris W Kuvshinoff; Thaer Khoury; Jihnhee Yu; Milind M Javle; Charles LeVea; Jeff Groth; Lionel J Coignet; John F Gibbs
Journal:  J Gastrointest Surg       Date:  2007-04       Impact factor: 3.452

3.  YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.

Authors:  Chen-Song Huang; Ying-Qin Zhu; Qiong-Cong Xu; Siyun Chen; Yue Huang; Guangyin Zhao; Xuhao Ni; Bo Liu; Wei Zhao; Xiao-Yu Yin
Journal:  Clin Transl Med       Date:  2022-06

4.  A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Authors:  Crystal S Denlinger; Neal J Meropol; Tianyu Li; Nancy L Lewis; Paul F Engstrom; Louis M Weiner; Jonathan D Cheng; R Katherine Alpaugh; Harry Cooper; John J Wright; Steven J Cohen
Journal:  Clin Colorectal Cancer       Date:  2014-01-04       Impact factor: 4.481

5.  Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma.

Authors:  Chunxiang Li; Xiaofu Li; Linfeng Wu; Zheng Jiang
Journal:  Technol Cancer Res Treat       Date:  2016-05-02

Review 6.  Intrahepatic cholangiocarcinoma: current perspectives.

Authors:  Stefan Buettner; Jeroen LA van Vugt; Jan Nm IJzermans; Bas Groot Koerkamp
Journal:  Onco Targets Ther       Date:  2017-02-22       Impact factor: 4.147

7.  Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer.

Authors:  Chiara Falcomatà; Stefanie Bärthel; Angelika Ulrich; Roland Rad; Günter Schneider; Dieter Saur; Sandra Diersch; Christian Veltkamp; Lena Rad; Fabio Boniolo; Myriam Solar; Katja Steiger; Barbara Seidler; Magdalena Zukowska; Joanna Madej; Mingsong Wang; Rupert Öllinger; Roman Maresch; Maxim Barenboim; Stefan Eser; Markus Tschurtschenthaler; Arianeb Mehrabi; Stephanie Roessler; Benjamin Goeppert; Alexander Kind; Angelika Schnieke; Maria S Robles; Allan Bradley; Roland M Schmid; Marc Schmidt-Supprian; Maximilian Reichert; Wilko Weichert; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

8.  The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.

Authors:  Antonello A Romani; Pellegrino Crafa; Silvia Desenzani; Gallia Graiani; Costanza Lagrasta; Mario Sianesi; Paolo Soliani; Angelo F Borghetti
Journal:  BMC Cancer       Date:  2007-12-21       Impact factor: 4.430

9.  Prognostic significance of snail expression in hilar cholangiocarcinoma.

Authors:  Dalu Kong; Jun Liang; Rong Li; Shihai Liu; Jigang Wang; Kejun Zhang; Dong Chen
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.